Table I.
Summary of most important changes in the WHO 2022 classification of kidney tumours.
| Renal Tumour Entity | Key changes in WHO 2022 |
|---|---|
| Papillary renal cell carcinoma (PRCC) | Subclassification into type 1 and type 2 PRCC no longer recommended Morphologic spectrum of PRCC expanded to include the following patterns: biphasic PRCC, papillary renal neoplasm with reverse nuclear polarity, and Warthin-like PRCC |
| Clear cell papillary renal cell tumour | Name change from “carcinoma” to “tumour” owing to benign behavior |
| TFE3-rearranged RCC and TFEB-altered RCC | Previously considered together as “MIT family of RCCs”. Now separated into two distinct types: TFE3-rearranged RCC and TFEB-altered RCC (that includes TFEB-rearranged RCC and TFEB-amplified RCC). |
| Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) | FH-deficient RCC is the preferred name over hereditary leiomyomatosis associated RCC |
| SMARCB1 (INI1)-deficient renal medullary carcinoma | Name change from former “medullary carcinoma” |
| Eosinophilic solid and cystic renal cell carcinoma (ESC RCC) | New entity (included under “Other renal tumours”) |
| Anaplastic lymphoma kinase-rearranged renal cell carcinoma (ALK-rearranged RCC) | New entity (included under “Molecularly defined renal carcinomas”) |
| ELOC (formerly TCEB1)-mutated RCC | New entity (included under “Molecularly defined renal carcinomas”) |
| Low-grade oncocytic tumour (LOT) | Emerging entity (included under “Other oncocytic tumours of the kidney”) |
| Eosinophilic vacuolated tumour (EVT) | Emerging entity (included under “Other oncocytic tumours of the kidney”) |
| Oncocytic renal neoplasms of low malignant potential NOS | Suggested name for eosinophilic/oncocytic tumours with borderline features between oncocytoma and chromophobe RCC that do not fit into any specific entity. This term should be used for a group of heterogeneous sporadic, eosinophilic/oncocytic tumours with borderline features (included under “Other oncocytic tumours of the kidney”). “Hybrid oncocytic tumors” is a suggested term for eosinophilic/oncocytic tumors with borderline features that occur in a hereditary setting, such as Birt-Hogg- Dubé syndrome. |